Four Japanese Firms Team Up to Make 3D Printed Regenerative Medicine Practical
Four Japanese companies have joined forces to develop mass cultivation technology for stem cells, aiming to make regenerative medicine using 3D printers more practical and affordable. The partnership, involving Kuraray Co., Cyfuse Biomedical K.K., Chiyoda Corp., and Zacros Corp., seeks to overcome the significant costs associated with large-scale stem cell cultivation.
The collaboration will share resources such as equipment, necessary substances, analysis methods, and safety verification techniques. Zacros will provide cultivation equipment, while Kuraray will offer substances to increase cultivation efficiency. The ultimate goal is to establish this mass cultivation technology by 2030, paving the way for commercial production of blood vessels, nerves, cartilage, and other tissues using 3D printers.
While specific details about the individuals leading these companies are not available, several prominent researchers and enterprises are active in this field. Notable companies include BioXell, Organovo Holdings, and Celavie Biosciences. Key figures driving regenerative medicine and 3D bioprinting include Anthony Atala and Keith Murphy, among others.
The partnership of these four Japanese companies marks a significant step towards making regenerative medicine using 3D printers more accessible. By sharing resources and expertise, they aim to establish mass cultivation technology for stem cells by 2030, opening new possibilities for tissue engineering and repair.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
